Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,752 questions · 6,648 findings · 688 reviews

No studies found 1,125 · 16.9%GRADE not reported 670 · 10.1%Very low 1,796 · 27%Low 1,685 · 25.3%Moderate 1,075 · 16.2%High 297 · 4.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Any systemic treatment vs placebo

Etanercept · people with chronic plaque psoriasis

Any systemic treatment probably leads to higher etanercept compared with placebo (moderate certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Tofacitinib · people with chronic plaque psoriasis

Any systemic treatment may leads to higher tofacitinib compared with placebo (low certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Apremilast · people with chronic plaque psoriasis

Any systemic treatment probably leads to higher apremilast compared with placebo (moderate certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Acitretin · people with chronic plaque psoriasis

It is very uncertain whether any systemic treatment changes acitretin compared with placebo (very low certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Ixekizumab · people with chronic plaque psoriasis

Any systemic treatment probably leads to higher ixekizumab compared with placebo (moderate certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Bimekizumab · people with chronic plaque psoriasis

Any systemic treatment showed no clear difference in bimekizumab compared with placebo (low certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Risankizumab · people with chronic plaque psoriasis

Any systemic treatment probably leads to lower risankizumab compared with placebo (moderate certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Ustekinumab · people with chronic plaque psoriasis

Any systemic treatment showed no clear difference in ustekinumab compared with placebo (moderate certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Guselkumab · people with chronic plaque psoriasis

Any systemic treatment showed no clear difference in guselkumab compared with placebo (moderate certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Adalimumab · people with chronic plaque psoriasis

Any systemic treatment showed no clear difference in adalimumab compared with placebo (moderate certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Brodalumab · people with chronic plaque psoriasis

Any systemic treatment showed no clear difference in brodalumab compared with placebo (moderate certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Secukinumab · people with chronic plaque psoriasis

Any systemic treatment showed no clear difference in secukinumab compared with placebo (moderate certainty).

2 findings from 1 review

Mitomycin C dacryocystorhinostomy vs dacryocystorhinostomy alone

Functional success, defined as the relief of epiphora · nasolacrimal duct obstruction

Mitomycin C dacryocystorhinostomy showed no clear difference in functional success, defined as the relief of epiphora compared with dacryocystorhinostomy alone (low certainty).

2 findings from 1 review

Mitomycin C dacryocystorhinostomy vs dacryocystorhinostomy alone

Anatomic success, defined as patency to lacrimal irrigation · nasolacrimal duct obstruction

Mitomycin C dacryocystorhinostomy showed no clear difference in anatomic success, defined as patency to lacrimal irrigation compared with dacryocystorhinostomy alone (low certainty).

2 findings from 1 review

Mitomycin C dacryocystorhinostomy vs dacryocystorhinostomy alone

Ostium size on nasal endoscopy · nasolacrimal duct obstruction

Mitomycin C dacryocystorhinostomy showed no clear difference in ostium size on nasal endoscopy compared with dacryocystorhinostomy alone (low certainty).

2 findings from 1 review